Category Archives: Ulcerative Colitis

Biosimilars are gaining acceptance by the health insurance industry, according to a new Avalere report. A survey of 45 health plans shows 81 percent of plans are covering at least one of two biosimilar products currently on the market, according to a survey of health insurers. Cost compared to the original treatment was the key factor for determining coverage, followed by a biosimilar's efficacy and safety of the product. However a recent Navigant study shows biosimilar drugs leads to a reduction in profits for most providers. [Also: Biosimilar drugs often translate to lower provider profits, says Navigant analysis] Biosimilars have the potential to reduce the cost of treatment, but the savings are not realized for most providers mainly due to the "buy-and-bill" reimbursement model for infused therapies. The Centers for Medicare and Medicaid Services incentivizes the use of biosimilars through reimbursement, but private payers generally don't, the Navigant study said. The Food and Drug Administration has approved five biosimilars, medicines that are highly similar to an original biologic used for treatment. They are not considered generic drugs. Two have launched, Zarxio and Inflectra. Neither sought an interchangeability designation from the FDA. Neither two years after the launch of Zarxio, it … Continue reading →

SILVIS -- As Dylan Meyer walked off the 18th green at TPC Deere Run on Tuesday wrapping up his practice round for the John Deere Classic, he was greeted by several children seeking autographs. Around the same time in the 18th skybox, Meyers University of Illinois teammate, Nick Hardy, was interacting with approximately 100 children as part of the First Tee Lunch & Learn program. Not that long ago, Meyer and Hardy were those youngsters trying to snatch a signature or get a high-five from one of their golfing heroes. I like growing the game and like kids in general, said Meyer, who also was involved in Tuesday afternoons Youth Clinic. Ive been in that position before, and it is still pretty fresh in my mind watching (Steve) Stricker come play in St. Louis when I was a kid. I was in shock seeing him so I know how these kids feel. I want to give back as much as I can. Meyer and Hardy are making their PGA Tour debuts this week in the Quad-Cities. Both received sponsor exemptions on the same day in late May from tournament director Clair Peterson. They are in the midst of successful careers … Continue reading →

Results from a recent study just released by Spherix Global Insights reveal the views of US gastroenterologists To continue reading this article and to access exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space you need to be logged into the site and have an active subscription or trial subscription. Please loginorsubscribe in order to continue reading. Claim a week's trial subscriptionby signing up for free today and receive our daily pharma and biotech news bulletin free of charge, forever. BiosimilarsBiotechnologyEntyvioGastro-intestinalsHospiraInflectraJanssenJohnson & JohnsonMarkets & MarketingPfizerStelaraUlcerative colitisUSA Access The Pharma Letter's latest news free for 7 days PLUS... you can receive the Pharma Letter headlines and news roundup email free forever Click here to take a free trial Unlimited access to The Pharma Letter site for a whole year Only 77 per month or 820 per year Click here to subscribe The rest is here: US gastroenterologists views on ulcerative colitis drugs - The Pharma Letter (registration) … Continue reading →

Ulcerative Colitis Drugs Market report provides key statistics on the market status of the Ulcerative Colitis Drugs Manufacturers and is a valuable source of guidance and direction for companies and individuals interested in the Ulcerative Colitis Drugs Industry. The Ulcerative Colitis Drugs industry report firstly announced the Ulcerative Colitis Drugs Market fundamentals: definitions, classifications, applications and market overview; product specifications; manufacturing processes; cost structures, raw materials and so on. Get PDF Sample of Ulcerative Colitis Drugs Market Report @ https://www.absolutereports.com/enquiry/request-sample/10732468 Ulcerative Colitis Drugs Market split by Application -Application 1, Application 2, Application 3 Ulcerative Colitis Drugs Market Segment by Regions (North America, Europe and Asia-Pacific) and the main countries (United States, Germany, United Kingdom, Japan, South Korea and China). Through the statistical analysis, the Ulcerative Colitis Drugs Market report depicts the global Industry Analysis, Manufacturers Analysis, Ulcerative Colitis Drugs Industry Development Trend, Sales Demand and Forecast to 2022. Table of Contents: Chapter 1 Ulcerative Colitis Drugs Market Overview 1.1 Definition 1.2 Classification Analysis 1.3 Application Analysis 1.4 Ulcerative Colitis Drugs Industry Chain Structure Analysis 1.5 Ulcerative Colitis Drugs Market Development Overview 1.6 Global Ulcerative Colitis Drugs Market Comparison Analysis 1.6.1 Global Import Market Analysis 1.6.2 Global Export Market Analysis 1.6.3 … Continue reading →

I have learned that living with Crohns can be a daily battle. Thats why us Crohnies are known as warriors! Even though there are many medications available to treat Crohns, sometimes surgery is necessary. Although Crohns can affect anywhere in the digestive tract, the colon is the most commonly affected portion of intestines. Total colectomy involves removing the entire colon. Partial colectomy involves removing part of the colon. Otherterms for this surgery include bowel resection and subtotal colectomy. Hemicolectomy involves removing the right or left portion of the colon. Proctocolectomy is the removal of the entire colon and the rectum. Many diseases and conditions that affect the colon can become dangerous. These include, but are not limited to, bleeding in the intestine, bowel obstructions, colon cancer, Crohns disease, ulcerative colitis, diverticulitis, and preventative surgery. Many people fearhaving a colectomy because of the risk of needing a ostomy bag. It is very importing to listen to your doctors directions when preparing for colon surgery. This also goes with having resections in small intestines. Typically prep starts a couple days prior to surgery, and can include: Step 1. If youre taking medications, gettingoff medications that can get in the way of healing … Continue reading →

Imagine feeling like a prisoner in your own body. Everything in life you once enjoyed is limited or gone all together. That is a common feeling for many people surviving with an ostomy a bowel or urinary diversion. Greta Powell, 70, of Killeen, is still in the recovery mode three months after her partial colectomy surgery at Scott & White Medical Center in Temple. She is learning the logistics of dealing with a colostomy and wearing a pouch beneath her clothes to collect her waste. It overwhelms you in the beginning, Powell said. How and when to change the bag and take care of yourself in a new way. Powell speaks in a soft, old-world accent from her native Netherlands, and looks a decade younger than her age. She and her military husband came to Fort Hood in 1985, but he died years ago. They had no children. In 2008, she had part of her colon removed due to cancer. All seemed well until three years ago when she experienced bladder infections. She was diagnosed with diverticulitis, which eventually lead to the surgery in March. At first, she was angry and scared. I couldnt move like I did and was … Continue reading →

SIOUX FALLS, S.D.- Thousands of motorcycles descended on Sioux Falls this weekend fora local annual event that helps a foundation grant wishes to children with life-threatening illnesses. For the past 22 years, organizers of Hot Harley Nights have been hosting the event for biker enthusiasts across the country to come together to explore the city of Sioux Falls and raise money for South Dakotas Make-A-Wish Foundation. This is a great opportunity to give back to a foundation, that gave us such a blessing in our life, says the mother of Make-A-Wish recipient Marta Fandel. Its the Fandels way of saying thank you to the organization, that was there for them during hard times. For three years now, the family has been volunteering at the Hot Harley Nights on behalf of Make-A-Wish South Dakota. In 2013, their son Kaiden was diagnosed with Ulcerative Colitis. There were times, where I didnt really feel like I was a kid. I mean, I felt like I was dealing with some hard stuff and I was forced to grow up really quick, but now Im doing good, says 2015 Make-A-Wish recipient Kaiden Fandel. After being nominated by his school nurse to the Make-A-Wish Foundation, Kaiden … Continue reading →

With phase 2 results expected to be released in the near future, JMP analyst Jason Butler upgraded his rating on Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) to Market Outperform with a $27 price target. We believe the stocks current valuation under-appreciates the potential for clinical and commercial success of either of these assets (Ralinepag in pulmonary arterial hypertension and strasimod in ulcerative colitis), Butler said. Ralinepag has demonstrated a superior preclinical profile to selexipag. Preclinical and early clinical studies have shown that ralinepag has the potential to be the best-in-class oral prostacyclin agonist. The drug is more potent than other oral nonprostanoid prostacyclin receptor agonists and has a superior pharmacokinetic profile, including lower Cmax, reduced peak-to-trough ratio and potential for once-daily dosing, Butler noted. This pushed Butler to believe ralinepag could be the best oral prostacyclin agonist for the treatment of pulmonary arterial hypertension. Arena has a couple of other strong assets in its portfolio. Specifically, Butler highlighted Etrasimod, which he sees Arena accelerating its time to market. We believe Arenas focus on these orphan indications for etrasimod can accelerate development timelines and provide a differentiated commercial opportunity vs. other S1P1 modulators. He also stated how Axovant Sciences Ltd (NYSE: AXON) … Continue reading →

Home Colon And Digestive Genes behind Crohns disease and ulcerative colitis uncovered Crohns disease and ulcerative colitis are types of inflammatory bowel disease (IBD). Research on IBDs continues as doctors learn more and more about these conditions, which affect the digestive system. Patients with IBDs often have to change their diets and suffer from symptoms likeabdominal pain, cramping, diarrhea, rectal bleeding, and extreme fatigue. Furthermore, these diseases can increase the risk of complications such as fissures or colon cancer. As inflammation takes over the intestines, colon symptoms worsen and a persons quality of life is negatively affected. Although there are some treatments available to help aid in the management of Crohns disease and ulcerative colitis, there is currently no cure. It isnt clear as to what causes Crohns disease or ulcerative colitis, but researchers are now closer to having a better understanding of its genetic link to inflammatory bowel disease. The researchers of the study looked at the genomes of nearly 68,000 people. After a closer look at the regions of the genome associated with IBD, 18 were traced to a single genetic variant with over 95 percent certainty. Uncovering the genes responsible for inflammatory bowel disease could improve treatment … Continue reading →

Ulcerative colitis is an inflammatory bowel disease for which new therapeutic strategies are greatly needed. A recent phase III clinical trial investigating the impact of a Janus Kinase (JAK) inhibitor tofacitinib, in the treatment of ulcerative colitis, provides a convincing proof of concept supporting the efficacy of this compound for induction and maintenance therapy. Ulcerative colitis is an inflammatory bowel disease characterized by increased bowel movements and bloody diarrhea. The disease is thought to be initiated by damage to the colon epithelium, which brings the colon microflora in contact with luminal immune cells and elicits an inflammatory immune response further damaging and preventing healing of the epithelium. Consequently, current treatments, including glucocorticoids and TNF-alpha monoclonal antibodies, aim to shut down this adverse immune response. Although usually effective, this category of treatments has two major pitfalls: 1) Owing to their immunosuppressive activity, they make patients more vulnerable to infections and 2) Some patients do not respond at all to the treatment or fail to maintain a sustained response. Therefore, new strategies are needed, especially for this latter group of patients. In addition to these aforementioned treatments, another attractive and promising therapeutic target is the Janus Kinase (JAK) family, an essential mediator … Continue reading →